Cannabis Abstinence and Neurocognitive Assessment in Adolescence (CANAA)

September 15, 2025 updated by: University Hospital Pilsen
Cannabis Abstinence and Neurocognitive Assessment in Adolescence

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Evaluate the development of cognitive functions following attainment of abstinence in a group of adolescents with cannabis dependence or harmful cannabis use. Abstinence is confirmed by toxicological testing.

Study Type

Observational

Enrollment (Estimated)

29

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Czechia
    • Czechia
      • Pilsen, Czechia, Czechia, 30100
        • Recruiting
        • University Hospital Pilsen
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jiri Podlipny, MD, Ph.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Description

Inclusion Criteria:

  • Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.

Exclusion Criteria:

  • psychiatric comorbidity - Dual diagnosis, including psychotic disorders, mood disorders, severe organic brain damage, or autism spectrum disorder, with the exception of compensated and stabilized anxiety disorder. Psychopharmacological treatment is permitted, except for antipsychotics prescribed for psychosis.
  • somatic comorbidity - Severe endocrine disorders such as diabetes mellitus, thyroid dysfunction, or severe cardiovascular disease.
  • Violation of abstinence between the first and second neuropsychological assessments, as well as severe decompensation of mental state requiring modification of established psychopharmacological treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1
Adolescents aged 15-18 years with a diagnosis of cannabis dependence or harmful cannabis use.
Diagnostic test: Neurocognitive assessment

Neurocognitive battery:

TMT-Trail Making Test Auditory Verbal Learning Test Stroop Test Tower of London (ToL), Shallice version Continuous Performance Test-Identical Pairs

Other psychometrics:

The level of dependence is quantified using the CAST (Cannabis Abuse Screening Test)

Diagnostic test: Urine toxicological assessment
Urine toxicological assessment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in performance TMT-B
Time Frame: 8 weeks
Change in performance on the Trail Making Test - Part B (TMT-B) [Time Frame: after 8 weeks of abstinence from cannabis]
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in performance on AVLT
Time Frame: 8 weeks
Change in performance on the Auditory Verbal Learning Test (AVLT) [Time Frame: after 8 weeks of abstinence]
8 weeks
Change in performance on the Stroop Test
Time Frame: 8 weeks
Change in performance on the Stroop Test [Time Frame: after 8 weeks of abstinence]
8 weeks
Change in performance on the Tower of London
Time Frame: 8 weeks
Change in performance on the Tower of London (Shallice version) [Time Frame: after 8 weeks of abstinence]
8 weeks
Change in performance on CPT-IP
Time Frame: 8 weeks
Change in performance on the Continuous Performance Test - Identical Pairs (CPT-IP) [Time Frame: after 8 weeks of abstinence]
8 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cannabis Abuse Screening Test versus degree of neurocognitive impairment
Time Frame: 8 weeks
Correlation between severity of cannabis dependence (Cannabis Abuse Screening Test, CAST) and degree of neurocognitive impairment [Time Frame: baseline and after 8 weeks of abstinence]
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital Pilsen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 3, 2024

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

August 31, 2029

Study Registration Dates

First Submitted

August 27, 2025

First Submitted That Met QC Criteria

August 27, 2025

First Posted (Estimated)

September 8, 2025

Study Record Updates

Last Update Posted (Estimated)

September 19, 2025

Last Update Submitted That Met QC Criteria

September 15, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CANAA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Not decided yet because we are still recruiting and waiting for primary outcome.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cannabis Dependence

Clinical Trials on Neurocognitive assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe